Chrysalis

Preclinical Services - Europe Les Oncins, B.P. 118 69593 L'ARBRESLE Cedex, France

Tel: +33 (0)4 74 01 63 63 Fax: +33 (0)4 74 01 63 99

E-mail: preclin.eu@chrysalisintl.com

Exhibit A CHRYSALIS

0644 '03 FEB 25 P1 54

STUDY SPONSOR

Laboratoires LAPHAL B.P. 7 13718 ALLAUCH CEDEX FRANCE

<u>STUDY TITLE</u>: Padina pavonica - Innocuity study following a single oral administration in the rat

REPORT NUMBER: 944/007

DATE . 30 December 1997

28 page-document

Author:
Caroline RUAT
CHRYSALIS
Preclinical Services - Europe
Les Oncins
B.P. 0118
69593 L'ARBRESLE CEDEX
FRANCE

TABLE OF CONTENTS

	Pages
GLP COMPLIANCE STATEMENT	3
QUALITY ASSURANCE	4
SUMMARY	5 & 6
GENERAL INFORMATION	7
SUBSTANCE(S) INFORMATION	8
PROTOCOL ADHERENCE	9
RESULTS Mortality Clinical signs Body weights Necropsy observations	11 12 13 & 14
APPENDIX • Signed protocol	

GLP COMPLIANCE STATEMENT

The study which is the subject of this report was performed at the request of Laboratoires LAPHAL.

I, the undersigned, declare that this study was conducted under my responsibility and in conformity with Standard Operating Procedures of the testing facility. It complied with: "O.E.C.D. Principles of Good Laboratory Practice" concerning Mutual Acceptance of Data in the Assessment of Chemicals dated 12 May 1981 (C (81) 30 Final), except that the formulation was not analysed for test article concentration.

Signature:

Name:

Caroline RUAT

Title '

Study Director

Date.

& December 1997

QUALITY ASSURANCE

STUDY TITLE: Padina payonica - Innocuity study following a single oral administration in the rat

Inspection of standard protocol was made in accordance with Standard Operating Procedure AQ-PROT 1.

Dates (day - month - year)				
Inspection	Report to Study Director	Report to Management		
29.12.1997	29.12.1997	29.12.1997		

Inspection(s) of data generated on this type of study was made in accordance with Standard Operating Procedure AQ-AUD 1.

Dates					
(day - month - year)					
Inspection	Report to Report Study Director Managen				
23.10.1997	-	23.10.1997			

Dates

Inspection(s) of procedures on this type of study was made in accordance wit

Procedure AQ-INSP 1.


on time type of study	,		
ith Standard Operating	(day - month - year)		
Inspected phase(s)	Inspection	Report to Study Director	Report to Management
Formulation Body weight Administration Clinical observations Necropsy	26.11.1997 02.10.1997 02.10.1997 14.10.1997 16 10.1997	- - -	26.11.1997 03.10.1997 03.10.1997 16.10.1997 16.10.1997

Other routine procedures used in this type of study were inspected regularly and reports made in accordance with Standard Operating Procedure AQ-INSP 1.

This report has been reviewed by the Quality Assurance Department, employing methods detailed in Standard Operating Procedure AQ-RAP 1. The reported methods and procedures were found to describe those used, and the results constituted an accurate representation of recorded data. Any data supplied by the sponsor were not subjected to review.

P. WITHERS, B. Sc.
(Quality Assurance Manager)

Date



5

SUMMARY

STUDY SPONSOR: Laboratoires LAPHAL

Padina pavonica - Innocuity study following a single oral administration in the rat

Compliance with guidelines:
O.E.C.D. n° 401 (1987),
E.E.C 92/69 - Annex V - method B1 (1992).

1. PROTOCOL

- The test article was administered once only, in suspension in water for injection and at the dose level of 2000 mg/kg, by the oral route (gavage) in the Sprague-Dawley rat (10 males + 10 females Supplier: Iffa-Crédo).
- Examinations for mortality and abnormal clinical signs were performed 15 minutes after intubation, then at 1, 2 and 4 hours, and then daily for the 14 day study period.
- All the animals were weighed on the day before treatment (day-1), immediately before administration of the test article (day 1), on days 8 and 15
- A necropsy was performed for all the animals after the final observation on day 15.

2. RESULTS

• Mortality (see results page 11)

No mortality was observed.

• Clinical signs (see results page 12)

There was no abnormal clinical sign in any of the animals during the observation period.

944/007

• Body weights (see results pages 13 & 14)

Body weight changes in the animals were not influenced by treatment.

• Necropsy observations (see results page 15)

No macroscopically detectable abnormality was noted in the animals euthanatized on study termination (Day 15).

3. CONCLUSION

 Based on the results obtained under the experimental conditions employed, no sign of toxicity was observed following a single oral administration at the dose level of 2000 mg/kg.

C. RUAT

Study Director

9 4 4 / 0 0 7

GENERAL INFORMATION

- TEST ARTICLE : Padina pavonica
- AIM OF THE STUDY to determine the innocuity of the test article in the rat following one single oral (gavage) administration

STUDY SPONSOR :

Address : Laboratoires LAPHAL
 B.P. 7
 13718 ALLAUCH
 FRANCE

· Study Monitor · Mme C. SALES

• TESTING FACILITY :

Address: CHRYSALIS
 Preclinical Services - Europe
 Les Oncins - BP 0118
 69593 L'ARBRESLE CEDEX
 FRANCE

Study Director . C. RUAT

• PROTOCOL N° 944/007-D of 15 October 1997, accepted on 16 October 1997

• SCHEDULE OF THE STUDY:

- Study initiation date (definitive protocol signed by the Study Director) :
 - 15 October 1997
- Study completion date (final report signed by the Study Director):
 - 30 December 1997

• RESPONSIBLE PERSONNEL:

- Study Director . C. RUAT, DUT Biologie Appliquée, Dip. EPHE.
- Quality Assurance Manager: P WITHERS, B. Sc.

SUBSTANCE(S) INFORMATION

TEST ARTICLE

· Denomination Padina pavonica

• Denomination for the study . 05423 J7 001

· Presentation : brown powder

• Purity: considered as 100 % for the study

Batch number: 23.01.97.02MStorage: at room temperature

· Expiry date: not supplied by the Sponsor

VEHICLE OF THE TEST ARTICLE

· Denomination . water for injection

Batch number : LD 3119

• Expiry date . October 1998

• Supplier : Laboratoire Biosedra, Louviers, France

• pH = 6.9

Conditions of measurement , the measurement was carried out under magnetic stirring. $T = 20.8 \, ^{\circ}\text{C}$

SUBSTANCE(S) ADMINISTERED

- The test article was prepared in a 10 % (W/V) suspension in the vehicle.
- pH of the 10 % suspension = 7.7
 Conditions of measurement: the measurement was carried out under magnetic stirring.
 T = 23.0 °C
- Frequency of preparations: on the day of administration.
- Stability of preparations: administered within 4 hours of preparation.

PROTOCOL ADHERENCE

The study was performed in accordance with the protocol, with the following deviation

. Slight variations of humidity were beyond the normal range (40 to 70 % R.H.), with a minimum of 28.2 % R.H.

This deviation was not considered to have affected the outcome or the objectives of the study.